Andrea Loehr - Concepedia

Author

Andrea Loehr

Clovis Oncology (United States)

Also Known As

A Loehr, A. LOEHR, A. Loehr, Andrea Loehr, Loehr, A, Loehr, Andrea

125

Publications

2.4K

Citations

H-Index

Concepts

All Affiliations

Clovis Oncology (United States)Institut Gustave Roussy Université Paris-Saclay Memorial Sloan Kettering Cancer Center Sarah Cannon Research Institute

About

Andrea Loehr is an author at Clovis Oncology (United States) specializing in medicine, oncology, and cancer therapeutics.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	8	8	377
2	Health Sciences	2	2	38
3	Engineering	1	1	17
4	Public Health	1	1	144
5	Cell Biology	1	1	17

Andrea Loehr

Publications

1.9K

Citations

H-Index

Page 1

	Year	Citations
Rucaparib in Men With Metastatic Castration-Resistant Prostate Cancer Harboring a<i>BRCA1</i>or<i>BRCA2</i>Gene Alteration Wassim Abida, Akash Patnaik, David Campbell, Journal of Clinical Oncology	2020	655
Rucaparib or Physician’s Choice in Metastatic Prostate Cancer Karim Fizazi, Josep M. Piulats, M. Neil Reaume, New England Journal of Medicine	2023	380
Genomic Analysis of Circulating Tumor DNA in 3,334 Patients with Advanced Prostate Cancer Identifies Targetable BRCA Alterations and AR Resistance Mechanisms Hanna Tukachinsky, Russell W. Madison, Jon Chung, Clinical Cancer Research	2021	186
Septicemia in 980 Patients at a University Hospital in Berlin: Prospective Studies During 4 Selected Years Between 1979 and 1989 H. F. Geerdes, Dan Ziegler, H. Lode, Clinical Infectious Diseases Proven SepticemiaPathogenic MicrobiologyKlebsiella PneumoniaeEscherichia ColiMortality Rates	1992	144
Rucaparib for the Treatment of Metastatic Castration-resistant Prostate Cancer Associated with a DNA Damage Repair Gene Alteration: Final Results from the Phase 2 TRITON2 Study Wassim Abida, David Campbell, Akash Patnaik, European Urology Genome InstabilityUrologyTriton2 StudyGenitourinary CancerMedicine	2023	79
Loss of heterozygosity as a marker of homologous repair deficiency in multiple myeloma: a role for PARP inhibition? Charlotte Pawlyn, Andrea Loehr, Cody Ashby, Leukemia	2018	62
Efficacy and safety of rucaparib in previously treated, locally advanced or metastatic urothelial carcinoma from a phase 2, open-label trial (ATLAS) Petros Grivas, Yohann Loriot, Rafael Morales‐Barrera, BMC Cancer	2021	57
Emergence of BRCA Reversion Mutations in Patients with Metastatic Castration-resistant Prostate Cancer After Treatment with Rucaparib Andrea Loehr, Arif Hussain, Akash Patnaik, European Urology Brca Reversion MutationsUrologySomatic VariantGenitourinary CancerMedicine	2022	55
Nivolumab plus rucaparib for metastatic castration-resistant prostate cancer: results from the phase 2 CheckMate 9KD trial Karim Fizazi, Margitta Retz, Daniel P. Petrylak, Journal for ImmunoTherapy of Cancer	2022	51
Rucaparib in patients presenting a metastatic breast cancer with homologous recombination deficiency, without germline BRCA1/2 mutation Anne Patsouris, Kadija Diop, Olivier Trédan, European Journal of Cancer	2021	44

Page 1